Holen Sie sich die Stockscreener-App
1.12
5.88%
-0.07
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ORGS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.19
Offen:
$1.12
24-Stunden-Volumen:
1,362
Relative Volume:
14.48
Marktkapitalisierung:
$N/A
Einnahmen:
$662.00K
Nettoeinkommen (Verlust:
$-29.02M
KGV:
-0.1318
EPS:
-8.5
Netto-Cashflow:
$-12.54M
1W Leistung:
-18.89%
1M Leistung:
-73.27%
6M Leistung:
-76.19%
1J Leistung:
-86.10%
1-Tages-Spanne:
$1.105
$1.12
1-Wochen-Bereich:
$1.105
$1.19
52-Wochen-Spanne:
$1.105
$1.19
Orgenesis Inc Stock (ORGS) Company Profile
Vergleichen Sie ORGS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORGS
Orgenesis Inc
|
1.105 | 0 | 662.00K | -29.02M | -12.54M | -8.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.57 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.55 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.60 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.08 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
288.35 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Orgenesis Inc Stock (ORGS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-12-20 | Eingeleitet | Dawson James | Buy |
Orgenesis Inc Aktie (ORGS) Neueste Nachrichten
Oncolytic Virus Cancer Therapy Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Orgenesis (NASDAQ:ORGS) Stock Price Down 6.6% – Time to Sell? - Defense World
Implementation of a Quality Management System for decentralized manufacturing of cell and gene therapy products -technical and regulatory considerations_ von der Leyen et al. -1 -Implementation of a Quality Management System for decentralized manufact - Frontiers
Orgenesis (NASDAQ:ORGS) Stock Price Down 3.6% – What’s Next? - Defense World
GLP-1 Receptor Agonist Market Exclusive Report with Detailed - openPR.com
Genital Warts Treatment Market Deep Research Report Highlights Key PlayersMerck & Co., Inc., Bausch Health - openPR.com
Orgenesis (NASDAQ:ORGS) Shares Down 5.5% – Time to Sell? - Defense World
GLP-1 Receptor Agonist Market Rising Demand and Growth Forecast - openPR.com
Regenerative Therapies Market in 2025-2032 Detailed Study - openPR.com
Orgenesis Delays Filing of Quarterly Report - TipRanks
Orgenesis Announces Stock Repurchase Plan Of Up To $10 Million - Reuters
GLP-1 Receptor Agonist Market Projected To Witness Substantial GRIVER COUNTRY - RIVER COUNTRY - NEWS CHANNEL NEBRASKA
Delisting of Securities of TLGY Acquisition Corporation; Target Global Acquisition I Corp.; Inception Growth Acquisition Limited; Healthcare AI Acquisition Corp.; Globalink Investment Inc.; BurTech Acquisition Corp; Mountain & Co. I Acquisition Corp.; Pearl Hol - The Manila Times
Nasdaq Announces Delisting of Multiple Companies' Securities Including Alpine 4 Holdings, Inc. and Orgenesis Inc. - Nasdaq
Delisting of Securities of TLGY Acquisition Corporation; Target Global Acquisition I Corp.; Inception Growth Acquisition Limited; Healthcare AI Acquisition Corp.; Globalink Investment Inc.; BurTech Acquisition Corp; Mountain & Co. I Acquisition... - The Globe and Mail
Delisting of Securities of TLGY Acquisition Corporation; Target Global Acquisition I Corp.; Inception Growth Acquisition Limited; Healthcare AI Acquisition Corp.; Globalink Investment Inc.; BurTech Acquisition Corp; Mountain & Co. I Acquisition Corp.; Pea - ADVFN
Press Release Distribution & PR Platform - ACCESS Newswire
GLP-1 Receptor Agonist Market Is Booming Worldwide 2025-2032: Verrica Pharmaceuticals, AbbVie Inc. - newstrail.com
ORGENESIS Earnings Preview: Recent $ORGS Insider Trading, Hedge Fund Activity, and More - Nasdaq
Analyzing Aadi Bioscience (NASDAQ:AADI) and Orgenesis (NASDAQ:ORGS) - Defense World
Orgenesis (NASDAQ:ORGS) Stock Price Up 3.1% – Here’s What Happened - Defense World
How can multimodal and modular cleanrooms satisfy all requirements? - European Pharmaceutical Manufacturer
Point-of-Care Cell and Gene Therapy Manufacturing Market Report 2025-2035Closed-System Bioreactors and AI Bioprocessing Set to Shape PoC Manufacturing by 2035ResearchAndMarkets.com - Bluefield Daily Telegraph
Orgenesis Delays 10-K Filing Amid Financial Challenges - TipRanks
Key Trend Shaping the Common Warts Market in 2025: Enhancing Treatment Efficacy Through Clinical Trials - WhaTech
ORGENESIS INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Cell therapy weekly: US$286 million acquisition expands CAR-T manufacturing and commercialization - RegMedNet
Genital Warts Market Growth: Projected to Reach $2.57 Billion by 2029 with an Impressive 5.4% CAGR - WhaTech
Top Companies Developing Cell Therapy Treatments For Diabetes in 2025 - BioInformant
Can This New Spinal Cord Treatment Technology Revolutionize a $7.5B Medical Market? - StockTitan
CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain - GlobeNewswire Inc.
CAR T-cell Therapy Clinical Trial Pipeline Experiences - GlobeNewswire
Orgenesis Featured in Special Report on Curing Diabetes - ACCESS Newswire
Hemogenyx Pharmaceuticals PLC Announces Final Results for the Year Ended 31 December 201829/04/2019 - ACCESS Newswire
Stromal Vascular Fraction Market Set to Grow Significantly, - GlobeNewswire
Stem Cell Therapy Market to Grow from $5.8 Billion in 2022 to $19.1 - openPR
Orgenesis Inc. Secures $5 Million Equity Investment, Moves Trading to OTCQXOrgenesis Inc. (NASDAQ: ORGS) recently entered into an Equity Purchase Agreement with Williamsburg Venture Holdings, LLC, a Nevada limited liability company. As per the agre - Defense World
Analysts’ Weekly Ratings Updates for Blueprint Medicines (BPMC) - Defense World
Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings - StockTitan
Regenerative Xenograft Market 2025-2032: Revenue Growth, Business Opportunities, Trends and Forecast - WICZ
Orgenesis (NASDAQ:ORGS) Stock Price Down 13.1% – What’s Next? - Defense World
UBS Group Lowers YETI (NYSE:YETI) Price Target to $43.00 - Defense World
Scrip Asks… What Does 2025 Hold For Biopharma? Part 1: The State Of The Biopharma Industry - News & Insights
Orgenesis announces director resignation - Investing.com
Critical Contrast: Orgenesis (NASDAQ:ORGS) vs. BridgeBio Pharma (NASDAQ:BBIO) - Defense World
Viral Vector Production (Research-use) Market Size to Hit USD 7.62 Bn by 2034 - BioSpace
Autologous Stem Cell and Non-Stem Cell-Based Therapies Market Opportunity Analysis and Forecast, 2024-2030 - openPR.com
Orgenesis Inc. sees insider transactions totaling $16,259 in sales By Investing.com - Investing.com India
7 Companies Owned by Pfizer - Investopedia
3D Bioprinting for Tissue and Organ Regeneration Market to Reach $424.3 Million by 2030 As Revealed In New ... - WhaTech
Orgenesis Inc. Reports Q3 2024 Financial Results - TipRanks
Finanzdaten der Orgenesis Inc-Aktie (ORGS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.69%
2.49%
Kapitalisierung:
|
Volumen (24h):